Again, these results suggested that BYL719 enhanced the anti-cancer effect of gefitinib by inhibiting p-AKT in the PI3K/AKT activation-induced gefitinib-resistance NSCLC cells in 3D culture. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.